Bispecific antisense oligonucleotides having binding sites directed against an autocrine regulated growth pathway and bcl-2 for the treatment of prostate tumors

Medical Oncology

Volumn 24, Issue 2, 2007, Pages 189-196

  Rubenstein, Marvin ^a,b   Tsui, Paulus ^a   Guinan, Patrick ^a,b,c  

^a HEKTOEN INSTITUTE OF MEDICINE   (United States)

^b RUSH UNIVERSITY MEDICAL CENTER   (United States)

^c UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

Antisense; Prostate cancer; Therapy

Indexed keywords

ANTINEOPLASTIC AGENT; ANTISENSE OLIGONUCLEOTIDE; EPIDERMAL GROWTH FACTOR RECEPTOR; LIPOFECTIN; MESSENGER RNA; MR1; MR12; MR2; MR24; MR4; MR42; PROTEIN BCL 2; TRANSFORMING GROWTH FACTOR ALPHA; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ANTISENSE THERAPY; ARTICLE; CELL STRAIN LNCAP; CODON; CONTROLLED STUDY; DRUG INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; MALE; PRIORITY JOURNAL; PROSTATE TUMOR;

ANTINEOPLASTIC AGENTS; AUTOCRINE COMMUNICATION; BASE SEQUENCE; BINDING SITES; HUMANS; MALE; MOLECULAR SEQUENCE DATA; NUCLEIC ACID CONFORMATION; OLIGONUCLEOTIDES, ANTISENSE; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-BCL-2; RECEPTOR, EPIDERMAL GROWTH FACTOR; TRANSFORMING GROWTH FACTOR ALPHA; TUMOR CELLS, CULTURED;

EID: 36248978135     PISSN: 13570560     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02698039     Document Type: Article

References (13)

1. Rubenstein M, Mirochnik Y, Chou P, Guinan P. Antisense oligonucleotide intralesional therapy for human PC-3 prostate tumors carried in athymic nude mice. J Surg Oncol 1996;62:194-200.
2. Yamanaka K, Miyake H, Zangemeister-wittke U, Jansen B, Gleave M. Novel bispecific antisense oligonucleotides inhibiting both Bcl-2 and Bcl-xL expression induce apoptosis and enhance chemosensitivity in human androgen-independent prostate cancer cells. Proc Am Assoc Cancer Res 2004;45:abstract #2930.
3. Rubenstein M, Tsui P, Guinan P. Construction of a bispecific antisense oligonucleotide containing multiple binding sites for the treatment of hormone insensitive prostate tumors. Med Hypotheses 2005;65:905-907.
4. Rubenstein M, Tsui P, Guinan P. Bispecific antisense oligonucleotides with multiple binding sites for the treatment of prostate tumors and their applicability to combination therapy. Methods Find Clin Pharmacol 2006;28:1-4.
5. Rubenstein M, Anderson KM, Tsui P, Guinan P. Synthesis of branched antisense oligonucleotides having multiple specificities: treatment of hormone insensitive prostate cancer. Med. Hypotheses 2006;67:1374-1379.
6. Lee BS, et al. Synthesis of polymeric prodrug Polycefin based on biodegradable poly (malic acid) for drug delivery. Proc Am Assoc Cancer Res 2006;97:258a.
7. Rubenstein M, Tsui P, Guinan P. A review of antisense oligonucleotides in the treatment of human disease. Drugs of the Future 2004;29:893- 909.
8. http://www.afhu.org/site/press_releases/news_lego.htm
9. Gleave M, et al. Progression to androgen independence is delayed by adjuvant treatment with antisense bcl-2 oligodeoxynucleotides after castration in the LNCaP prostate tumor model. Clin Cancer Res 1999;5:2891- 898.
10. Zamecnik PC, Stephenson ML. Inhibition of Rous sarcoma virus replication and transformation by a specific deoxynucleotide. Proc Natl Acad Sci USA 1979;75:280-284.
11. Tsui P, Rubenstein M, Guinan P. Synergistic effects of combination therapy employing antisense oligonucleotides with traditional chemotherapeutics in the PC-3 prostate cancer model. Med Oncol 2004;21:339-348.
12. Rubenstein M, Slobodskoy L, Mirochnik Y, Guinan P. Inhibition of PC-3 prostate cancer cell growth in vitro using both antisense oligonucleotides and Taxol. Med Oncol 2003;20:29-35.
13. Mirochnik Y, Rubenstein M, Guinan P. Two constructed antibody derived delivery vehicles for targeting oligodeoxynucleotides to prostate tumors expressing prostate specific antigen. Drug Del 2004;11:161-167.